FDA approves Icotyde, a new oral IL-23 therapy for plaque psoriasis

CURRENT FULL VERSION: Johnson & Johnson has won FDA approval for Icotyde, or icotrokinra, for moderate-to-severe plaque psoriasis, adding a once-daily oral option for adults and adolescents age 12 and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. The March 18, 2026 approval gives J&J what it describes as the first and only targeted oral peptide that blocks the IL-23 receptor, a notable milestone in a psoriasis market long dominated by injectable biologics and, more recently, oral small molecules. (investor.jnj.com)

The approval follows J&J’s July 21, 2025 NDA submission, which leaned on the company’s Phase 3 ICONIC program: ICONIC-LEAD, ICONIC-TOTAL, and the duplicate head-to-head ICONIC-ADVANCE 1 and 2 studies. In that filing, J&J positioned icotrokinra as a first-in-class oral peptide designed to selectively block the IL-23 receptor, and highlighted both placebo-controlled efficacy and superiority versus deucravacitinib in the ADVANCE trials. (s203.q4cdn.com)

Key details from the approval package and company materials show how broadly J&J tried to build the label narrative. The company said the Phase 3 program enrolled about 2,500 patients across adults and adolescents, included patients with psoriasis affecting high-impact sites such as the scalp and genitals, and showed favorable safety findings with adverse event rates close to placebo through Week 16 and no new safety signals through Week 52. In the head-to-head studies, J&J reported that about 70% of patients achieved clear or almost clear skin on the Investigator’s Global Assessment scale, and 55% achieved PASI 90 at Week 16. (drugs.com)

J&J and affiliated sources framed the approval as more than just another psoriasis launch. In the company’s announcement, Henry Ford Health dermatologist Linda Stein Gold said the drug combines skin clearance, a favorable safety profile, and the convenience of a once-daily pill. J&J also tied the approval to evolving International Psoriasis Council guidance encouraging earlier movement to systemic therapy when topical cycling isn’t delivering meaningful improvement. The National Psoriasis Foundation’s CEO, according to J&J’s release, said a new systemic option could change treatment conversations for patients. Those comments come from company communications, so they should be read as supportive stakeholder reaction rather than independent post-approval critique. (investor.jnj.com)

For veterinary professionals, the story is less about psoriasis itself and more about platform direction. Icotrokinra reflects a broader pharmaceutical push to create orally delivered, highly targeted immunology therapies that aim for biologic-like performance without injections. That matters because similar design logic, selective pathway blockade, chronic-disease convenience, and adherence-friendly dosing, increasingly shapes expectations across therapeutic areas, including animal health R&D and pet parent conversations about long-term immune-mediated disease management. This is an inference from the human drug development trend rather than a direct statement from the companies, but it’s supported by how J&J and Protagonist describe the molecule’s mechanism and lifecycle ambitions. (irp.cdn-website.com)

There’s also a competitive angle worth noting. STAT described Icotyde as a first-of-its-kind psoriasis pill designed to emulate the effects of blockbuster IL-23 biologics without needles, underscoring why the approval drew attention beyond dermatology. That competitive backdrop may tighten further: Takeda presented Phase 3 LATITUDE data at AAD 2026 for oral TYK2 inhibitor zasocitinib in moderate-to-severe plaque psoriasis and said it plans regulatory submissions beginning in its fiscal 2026. According to PharmaShots’ summary of the company release, the two pivotal studies enrolled 693 and 1,108 adults, respectively, and showed clear separation from both placebo and apremilast at Week 16. In PsO 3001, 71.4% of patients on zasocitinib achieved sPGA 0/1 versus 10.7% on placebo and 32.1% on apremilast; PASI 90 and PASI 100 rates were 61.3% and 33.4%, versus 5% and 0.7% for placebo and 16.8% and 2.9% for apremilast. In PsO 3002, 69.2% achieved sPGA 0/1 versus 12.6% and 29.7%, while PASI 90 and PASI 100 rates were 51.9% and 25.2% versus 4% and 1.1% for placebo and 15.9% and 4.3% for apremilast. Takeda also highlighted rapid Week 4 PASI 75 responses and durability above 90% at Week 60. If Icotyde delivers on efficacy, safety, and convenience in real-world use, it could still put pressure on both injectable brands and other oral entrants in immune-mediated disease, but it is entering a market where the oral innovation race is clearly accelerating. (statnews.com) (pharmashots.com)

Why it matters: For clinicians and industry watchers, this approval highlights how oral peptide engineering is starting to move from concept to commercial reality in immunology. That has implications for future pipeline strategy, translational research interest, and the standard that pet parents may increasingly expect: targeted treatment, simpler administration, and fewer tradeoffs between convenience and efficacy. It also lands in a field where other oral targeted agents are posting strong late-stage data, reinforcing that cytokine-pathway modulation and adjacent immune signaling targets remain commercially and scientifically active areas to watch. (investor.jnj.com) (pharmashots.com)

What to watch: Watch the US launch, formulary and reimbursement decisions, and the next readouts in icotrokinra’s broader program, which company materials say includes ongoing or planned development in psoriatic arthritis, ulcerative colitis, and Crohn’s disease. Also watch how quickly the competitive oral psoriasis landscape evolves if Takeda follows through on planned filings for zasocitinib after its Phase 3 wins over placebo and apremilast. (irp.cdn-website.com) (pharmashots.com)